View Older Stories View More Recent Stories

Aug 3, 2020 06:00AM Exact Sciences to participate in August investor conference
Jul 30, 2020 04:05PM Exact Sciences Announces Second Quarter 2020 Results
Jul 8, 2020 06:00AM Exact Sciences schedules annual meeting, second quarter 2020 earnings call
Jun 16, 2020 08:03AM Exact Sciences (EXAS) Says Oncotype DX Genomic Prostate Score Result Shows for the First Time the Value of the Test to Guide Treatment Plans for Unfavorable Intermediate-Risk Prostate Cancer Patients
Jun 16, 2020 08:00AM Oncotype DX Genomic Prostate Score® Result Shows for the First Time the Value of the Test to Guide Treatment Plans for Unfavorable Intermediate-Risk Prostate Cancer Patients
Jun 15, 2020 09:30AM Founder and Former Chairman & CEO of Exact Sciences Stanley Lapidus Joins PAVmed Subsidiary Lucid Diagnostics as Strategic Advisor
May 29, 2020 08:00AM Exact Sciences Showcases Continued Progress in Cancer Diagnostics at ASCO 2020
May 26, 2020 06:00AM Exact Sciences to participate in June investor conferences
May 14, 2020 06:25AM Exact Sciences (EXAS) Announces New Oncotype DX Real-world Evidence Shows for First Time Practice-changing Impact of TAILORx Results
May 14, 2020 06:00AM New Oncotype DX® Real-world Evidence Shows for the First Time the Practice-changing Impact of TAILORx Results
May 6, 2020 04:05PM Exact Sciences Announces First Quarter 2020 Results
May 5, 2020 10:30AM New Model Shared at Digestive Disease Week (DDW) Demonstrates the Value of Cologuard® When Using Real-World Adherence Rates for Comparing Colorectal Cancer Screening Methods
May 4, 2020 06:00AM Exact Sciences to participate in May investor conference
Apr 8, 2020 06:00AM Exact Sciences schedules first-quarter 2020 earnings call
Apr 2, 2020 06:00AM Exact Sciences Highlights The Opportunity To Seek Screening With Cologuard® Through Telehealth
Mar 19, 2020 06:08AM Exact Sciences (EXAS) Withdraws 1Q & FY20 Outlook; Provides Business Response to COVID-19 Pandemic
Mar 19, 2020 06:00AM Exact Sciences Takes Action during COVID-19 Pandemic
Mar 5, 2020 01:02AM Press release Biocartis Group NV: BIOCARTIS ANNOUNCES 2019 RESULTS AND 2020 OUTLOOK
Mar 3, 2020 04:27PM Exact Sciences (EXAS) Reports Acquisitions of Paradigm Diagnostics Inc. and Viomics Inc.
Mar 3, 2020 04:05PM Exact Sciences Extends Leadership In Advanced Cancer Diagnostics With Acquisitions Of Paradigm And Viomics
Feb 26, 2020 06:00AM Exact Sciences to participate in March investor conferences
Feb 11, 2020 04:05PM Exact Sciences Announces Fourth-Quarter 2019 Results
Jan 27, 2020 06:00AM Exact Sciences schedules fourth-quarter, full-year 2019 earnings call
Jan 13, 2020 06:45AM Exact Sciences (EXAS) Prelim. Q4 Revenue Tops Consensus
Jan 12, 2020 07:00PM Exact Sciences Announces Preliminary Fourth Quarter 2019 Results
Jan 2, 2020 06:00AM Exact Sciences to participate in J.P. Morgan Healthcare Conference
Dec 12, 2019 06:13AM Exact Sciences (EXAS) Highlights New Outcomes Data from Two Large Population-Based Evaluating Oncotype DX Breast Recurrence Score to Guide Chemotherapy Treatment
Dec 12, 2019 06:00AM New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score® to Guide Chemotherapy Treatment in Young Patients with Node-negative or Node-positive Early-stage Breast Cance
Dec 4, 2019 04:30PM Dr. David Ahlquist, co-inventor of Cologuard, named a Fellow of the National Academy of Inventors
Nov 26, 2019 06:00AM Exact Sciences to participate in December investor conference
Nov 8, 2019 08:04AM Exact Sciences (EXAS) Presents Data On Blood-Based Test For Detection Of Hepatocellular Carcinoma, Earns FDA Breakthrough Device Designation
Nov 8, 2019 08:03AM Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company
Nov 8, 2019 08:00AM Exact Sciences Presents Data On Blood-Based Test For Detection Of Hepatocellular Carcinoma, Earns FDA Breakthrough Device Designation
Nov 7, 2019 01:57PM Genomic Health (GHDX) Holders Approve Merger with Exact Sciences (EXAS)
Nov 7, 2019 01:55PM Genomic Health Stockholders Approve Proposed Acquisition by Exact Sciences
Nov 1, 2019 06:00AM Exact Sciences to participate in November investor conferences
Oct 29, 2019 04:12PM Exact Sciences (EXAS) Presents New Stool-Based Colorectal Cancer Screening Performance Data, Initiates Prospective Screening Study
Oct 29, 2019 04:05PM Exact Sciences reports third-quarter revenue growth of 85 percent to $219 million
Oct 29, 2019 04:05PM Exact Sciences Presents New Stool-Based Colorectal Cancer Screening Performance Data, Initiates Prospective Screening Study
Oct 14, 2019 06:00AM Exact Sciences And Mayo Clinic Initiate 150,000 Patient, 7-Year Study To Evaluate Real-World Impact Of Cologuard®
Oct 8, 2019 06:00AM Exact Sciences schedules third-quarter 2019 earnings call
Sep 23, 2019 05:50AM Exact Sciences (EXAS) Reports FDA Approval for Use of Cologuard in Younger Americans, Ages 45 To 49
Sep 23, 2019 05:45AM Cologuard® Gains FDA Approval For Use In Younger Americans, Ages 45 To 49
Sep 19, 2019 08:35AM Exact Sciences Named One of the 2019 Best Workplaces for Women by Great Place to Work® and FORTUNE
Sep 10, 2019 10:00AM Patrick Terry announced as first Chief Commercial Officer of SomaLogic
Aug 30, 2019 09:15AM Exact Sciences to participate in September investor conference
Aug 2, 2019 06:00AM Exact Sciences to participate in August investor conference
Jul 29, 2019 07:02AM Exact Sciences (EXAS) to combine with Genomic Health (GHDX) for $72/share in cash and stock transaction valued at $2.8 billion
Jul 29, 2019 07:01AM Second-quarter revenue increased 94 percent to $200 million and Cologuard test volume increased 93 percent to 415,000
Jul 29, 2019 07:00AM Exact Sciences and Genomic Health to Combine, Creating Leading Global Cancer Diagnostics Company
View More Recent Stories View Older Stories